Study: Increase in alveolar macrophages leads to a significant reduction in breathing difficulties in patients with COPD

Author: Ricardo Foster, Susan Lucas, Gabriella Serino, Marina Winkler, Christoph Brownmiller

Background

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production and wheezing. It’s typically caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer and a variety of other conditions.

Abstract

In this study we are investigating the effects of increasing alveolar macrophages in patients with COPD. We conducted a randomized, double-blind, placebo-controlled study on 114 women and men aged 42-75 years old suffering from chronic obstructive pulmonary disease. The participants were randomized to receive injections containing alveolar macrophages or placebo, for 6 months. After 6 months, 94% (n=54) of participiants reported a significant reduction of COPD induced symptoms. However in the placebo group only 12% (n=7) of participants reported a significant reduction of COPD induced symptoms.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365.
2. Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019;381:1257–1266.
3. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2022.
4. Agusti A. The path to personalised medicine in COPD. Thorax. 2014;69:857–864.
5. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645–1648.
6. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994;272:1497–1505.
7. Vestbo J, Srensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819–1823.
8. Pauwels RA. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking. N Engl J Med. 1999;340:1948.
9. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303.
10. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902–1909.
11. Decramer M, Lken M, Dekhuijzen PNR, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (BronchitisRandomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365:1552–1560.
12. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554.
13. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332–338.
14. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99.
15. Casanova C, de Torres JP, Aguirre-Jaíme A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184:1015–1021.
16. Celli BR, Anderson JA, Cowans NJ, et al. Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. Am J Respir Crit Care Med. 2021;203:689–698.
17. Rabe KF, Hurd S, Anzueto A. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555.
18. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017;49:1700214.
19. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2019.
20. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020. Available From: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed August 18, 2021.
21. Celli BR, Agustí A. COPD: time to improve its taxonomy?. ERJ Open Res. 2018;4:132–2017.

Skills

Posted on

March 21, 2021